Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1136/annrheumdis-2014-206809 http://scihub22266oqcxt.onion/10.1136/annrheumdis-2014-206809 25817717!ä!25817717 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Ann+Rheum+Dis 2015 ; 74 (8): 1621-5 Nephropedia Template TP {{tp|p=25817717|t=2015. Stimulators of soluble guanylate cyclase (sGC) inhibit experimental skin fibrosis of different aetiologies |pdf=|usr=}}{{25817717}} gab.com Text Stimulators of soluble guanylate cyclase (sGC) inhibit experimental skin fibrosis of different aetiologies JO: Ann Rheum Dis http://www.kidney.de/pget.php?&tw=1&pmid=25817717 #FOAvip OBJECTIVES: Stimulators of the soluble guanylate cyclase (sGC) have recently been shown to inhibit transforming growth factor-beta signalling. Here, we aimed to demonstrate that riociguat, the drug candidate for clinical trials in systemic sclerosis (SSc), is effective in experimental fibrosis and to compare its efficacy to that of phosphodiesterase V inhibitors that also increase the intracellular levels of cyclic guanosine monophosphate. METHODS: The antifibrotic effects of riociguat and sildenafil were compared in the tight-skin 1 model, in bleomycin-induced fibrosis and in a model of sclerodermatous chronic graft-versus-host-disease (cGvHD). Doses of 0.1-3 mg/kg twice a day for riociguat and of 3-10 mg/kg twice a day for sildenafil were used. RESULT: Riociguat dose-dependently reduced skin thickening, myofibroblast differentiation and accumulation of collagen with potent antifibrotic effects at 1 and 3 mg/kg. Riociguat also ameliorated fibrosis of the gastrointestinal tract in the cGvHD model. The antifibrotic effects were associated with reduced phosphorylation of extracellular signal-regulated kinases. Sildenafil at doses of 3 and 10 mg/kg exerted mild antifibrotic effects that were significantly less pronounced compared with 1 and 3 mg/kg riociguat. CONCLUSIONS: These data demonstrated potent antifibrotic effects of riociguat on experimental skin and organ fibrosis. These findings suggest a role for riociguat for the treatment of fibrotic diseases, especially for the treatment of SSc. A phase II study with riociguat in patients with SSc is currently starting. Twit Text FOAVip Stimulators of soluble guanylate cyclase (sGC) inhibit experimental skin fibrosis of different aetiologies ????Ann Rheum Dis http://www.kidney.de/pget.php?&tw=1&pmid=25817717 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=25817717 #FOAvip English Wikipedia <ref>{{Cite pmid|25817717}}</ref> Stimulators of soluble guanylate cyclase (sGC) inhibit experimental skin fibrosis of different aetiologies #MMPMID25817717 Dees C; Beyer C; Distler A; Soare A; Zhang Y; Palumbo-Zerr K; Distler O; Schett G; Sandner P; Distler JH Ann Rheum Dis 2015[Aug]; 74 (8): 1621-5 PMID25817717show ga OBJECTIVES: Stimulators of the soluble guanylate cyclase (sGC) have recently been shown to inhibit transforming growth factor-beta signalling. Here, we aimed to demonstrate that riociguat, the drug candidate for clinical trials in systemic sclerosis (SSc), is effective in experimental fibrosis and to compare its efficacy to that of phosphodiesterase V inhibitors that also increase the intracellular levels of cyclic guanosine monophosphate. METHODS: The antifibrotic effects of riociguat and sildenafil were compared in the tight-skin 1 model, in bleomycin-induced fibrosis and in a model of sclerodermatous chronic graft-versus-host-disease (cGvHD). Doses of 0.1-3 mg/kg twice a day for riociguat and of 3-10 mg/kg twice a day for sildenafil were used. RESULT: Riociguat dose-dependently reduced skin thickening, myofibroblast differentiation and accumulation of collagen with potent antifibrotic effects at 1 and 3 mg/kg. Riociguat also ameliorated fibrosis of the gastrointestinal tract in the cGvHD model. The antifibrotic effects were associated with reduced phosphorylation of extracellular signal-regulated kinases. Sildenafil at doses of 3 and 10 mg/kg exerted mild antifibrotic effects that were significantly less pronounced compared with 1 and 3 mg/kg riociguat. CONCLUSIONS: These data demonstrated potent antifibrotic effects of riociguat on experimental skin and organ fibrosis. These findings suggest a role for riociguat for the treatment of fibrotic diseases, especially for the treatment of SSc. A phase II study with riociguat in patients with SSc is currently starting. |Animals[MESH] |Disease Models, Animal[MESH] |Dose-Response Relationship, Drug[MESH] |Fibrosis[MESH] |Guanylate Cyclase/*drug effects[MESH] |Mice[MESH] |Mice, Inbred Strains[MESH] |Phosphodiesterase 5 Inhibitors/pharmacology[MESH] |Pyrazoles/administration & dosage/*pharmacology/therapeutic use[MESH] |Pyrimidines/administration & dosage/*pharmacology/therapeutic use[MESH] |Scleroderma, Systemic/drug therapy[MESH] |Sildenafil Citrate/pharmacology[MESH]Stimulators of soluble guanylate cyclase (sGC) inhibit experimental sk(epmc).pdf DeepDyve Pubget Overpricing